Tomorrow’s medicines with today’s drug substances

Sponsored by: Recipharm

Focused on:

  • Drug Delivery Innovation
  • New Dosage Forms With Existing API:s

Date: 15 September


Time: 3PM London/10AM New York

Tomorrow’s medicines with today’s drug substances

Developing new pharmaceutical products is difficult in today’s environment. Products based on new chemical entities (NCEs) have the potential to generate huge profits, but the development process is long (often 10 years), costs are high (about $ 1 billion) and the risk of failure is great. In contrast, the development of generics is faster and much less costly. However, profits are generally small with a decreasing trend due to fierce competition. An interesting segment is new products using new dosage forms and existing active pharmaceutical ingredients (APIs) - known as “drug delivery innovation.’ Such products offer an alternative as development timelines are shorter, costs are significantly less, and a certain degree of market exclusivity can be gained. Consequently, these products can be highly profitable.

Register Now for this webinar on Tomorrow’s medicines with today’s drug substances.

Presented by

Torkel Gren, PhD,

Science and Technology Officer

Torkel is Senior Director, Science & Technology Officer at Recipharm AB. He holds degrees in Pharmacy and Business Administration as well a PhD in Pharmaceutics (Uppsala University). He has worked in the pharmaceutical industry since 1988 and has held a number of scientist and manager positions in Europe and the US. He was lead formulator and co-inventor of Detrol OD/Detrusitol SR. Torkel is vice chairman of the board of the Swedish Pharmaceutical Society.

Aaron Small,

Vice President Global Development Sales

Aaron Small is Vice President Global Development Sales at Recipharm. He holds a BSBA degree in Marketing and a MBA and has been a part of Recipharm since 2011. During his time in Recipharm he has contributed to business development activities for both development and manufacturing services. In addition Aaron has been a part of brand development and deployment for the North American market.

Key Learning Objectives

  • How to achieve product exclusivity and shorter development timelines through drug delivery innovation
  • The importance of understanding patient needs
  • The need for collaboration between formulation, regulatory affairs, patient and marketing experts
  • A case study involving an advanced fixed dose combination product for patients with Parkinson’s disease will also be discussed.


  • Analytical services - Manager/Director/Head/VP
  • CMC - Manager/Director/Head/VP
  • Development - Manager/Director/Head/VP
  • Formulation development - Manager/Director/Head/VP
  • Pharmaceutical development -Manager/Director/Head/VP
  • Chemistry/Medicinal Chemistry -Manager/Director/Head/VP
  • Founder and CEO
  • Procurement - Manager/Director/Head/VP
  • CSO
  • COO